Spots Global Cancer Trial Database for A Post-marketing Surveillance Study to Assess the Safety of Cervarix (GlaxoSmithKline [GSK] Biologicals' Human Papillomavirus [HPV] -16/18 Vaccine), When Administered According to the Approved Prescribing Information (PI) in Korea
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Post-marketing Surveillance Study to Assess the Safety of Cervarix (GlaxoSmithKline [GSK] Biologicals' Human Papillomavirus [HPV] -16/18 Vaccine), When Administered According to the Approved Prescribing Information (PI) in Korea
Official Title: Post-marketing Surveillance of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV)-16/18 Vaccine, Cervarix When Administered According to the Approved Prescribing Information in Korea
Study ID: NCT03671369
Conditions
Study Description
Brief Summary: The purpose of this post-marketing surveillance (PMS) study is to collect safety information on the use of Cervarix upon the expanded indication to anal cancer to both women and men (at least 600 Korean women and men) within 30 days after each vaccination dose, when administered according to the approved prescribing information (PI) in Korea in a real health care setting over a period of 4 years.
Detailed Description:
Eligibility
Minimum Age: 9 Years
Eligible Ages: CHILD, ADULT
Sex: ALL
Healthy Volunteers: Yes
Locations
GSK Investigational Site, Busan, , Korea, Republic of
GSK Investigational Site, Chungcheongnam-do, , Korea, Republic of
GSK Investigational Site, Daegu, , Korea, Republic of
GSK Investigational Site, Gongju-si, Chungcheongnam-do, , Korea, Republic of
GSK Investigational Site, Gwangju, , Korea, Republic of
GSK Investigational Site, Gyeonggi-do, , Korea, Republic of
GSK Investigational Site, Gyeonggi-do, , Korea, Republic of
GSK Investigational Site, Gyeongsangbuk-do, , Korea, Republic of
GSK Investigational Site, Gyeongsangbuk-do, , Korea, Republic of
GSK Investigational Site, Incheon, , Korea, Republic of
GSK Investigational Site, Jeollabuk-do, , Korea, Republic of
GSK Investigational Site, Jeollabuk-do, , Korea, Republic of
GSK Investigational Site, Jeonju-si, Jeollabuk-do, , Korea, Republic of
GSK Investigational Site, Jeonju-si,Jeollabuk-do, , Korea, Republic of
GSK Investigational Site, Seoul, , Korea, Republic of
GSK Investigational Site, Seoul, , Korea, Republic of
GSK Investigational Site, Seoul, , Korea, Republic of
GSK Investigational Site, Seoul, , Korea, Republic of
GSK Investigational Site, Seoul, , Korea, Republic of
GSK Investigational Site, Seoul, , Korea, Republic of
GSK Investigational Site, Seoul, , Korea, Republic of
GSK Investigational Site, Seoul, , Korea, Republic of
GSK Investigational Site, Seoul, , Korea, Republic of
GSK Investigational Site, Seoul, , Korea, Republic of
GSK Investigational Site, Seoul, , Korea, Republic of
GSK Investigational Site, Seoul, , Korea, Republic of
GSK Investigational Site, Suwon-si, Gyeonggi-do, , Korea, Republic of
GSK Investigational Site, Suwon-si, Gyeonggi-do, , Korea, Republic of
GSK Investigational Site, Yangju-si, Gyeonggi-do, , Korea, Republic of
Contact Details
Name: GSK Clinical Trials
Affiliation: GlaxoSmithKline
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
